Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts
The present study demonstrated that the combination of rMETase, cisplatinum, and ivermectin exerts selective synergy on lung-cancer cells, which was not observed on normal fibroblasts. Moreover, the present combination therapy has a strong synergistic efficacy at early time points on the lung-cancer cells. Further studies are warranted to elucidate the underlying mechanisms of synergy of the present combination treatment selectively on cancer cells and to evaluate the <i>in vivo</i> efficacy and safety of the present treatment strategy.
Authors
- Shukuan Li
- Byung Mo Kang (ORCID: https://orcid.org/0000-0003-0900-094X)
- Yohei Asano (ORCID: https://orcid.org/0000-0002-8777-6076)
- Katsuhiro Hayashi (ORCID: https://orcid.org/0000-0001-8665-2154)
- Norio Yamamoto (ORCID: https://orcid.org/0000-0002-7250-625X)
- Satoru Demura (ORCID: https://orcid.org/0000-0002-5703-3802)
- Robert M. Hoffman (ORCID: https://orcid.org/0000-0002-0049-0041)
- Takashi Higuchi (ORCID: https://orcid.org/0000-0003-2896-4939)
- Hiroyuki Tsuchiya (ORCID: https://orcid.org/0000-0003-0730-7921)
- KOHEI MIZUTA
- HIROAKI KIMURA
- Kentaro Igarashi (ORCID: https://orcid.org/0000-0003-2278-1736)
- Sei Morinaga (ORCID: https://orcid.org/0000-0003-2961-9432)
- Jin-Soo Kim (ORCID: https://orcid.org/0000-0002-1847-3741)
- Qinghong Han
- Shinji Miwa
- YUTA MIYASHI
Institutions
- Kanazawa University (JP)
- University of California San Diego (US)
- AntiCancer (United States) (US)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17875
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00